A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients

Stopped early · Phase 2

Conditions studied: Breast Neoplasms

In brief

The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer.

Key facts

Study ID

NCT00263211

Run by

Washington University School of Medicine

People needed

48

Starts

2006-01-01

Expected to finish

2009-09-01

Last updated by the study team

2017-03-15

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women with metastatic breast cancer who are completing planned course of chemotherapy with planned treatment break
• On stable hormone therapy for at least 2 months are also eligible for the study
• Estimated survival of at least 3 months
• No platelet inhibitor therapy within 1 month of study entry
• Platelets ≥ 100,000
• Coagulation screening tests within normal range (INR between 0.81 and 1.20)
• Normal kidney and liver function as defined by:
• Aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase (SGOT))/alanine aminotransferase(ALT) ≤ 2 x Institutional Normal
• Creatinine ≤ 2 x Institutional Normal
• Able to provide signed, informed consent.

You may not qualify if…

• Patients going on to surgery
• Patients with a serious bleeding disorder that make them inappropriate candidates for NSAID therapy
• Patients with history of significant bleeding related to peptic ulcer disease
• Patients on standing doses of NSAIDS or platelet function inhibitors
• Patients on standing doses of anti-coagulants

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.